Allogeneic stem cell transplantation for evans syndrome

Y. Oyama, E. B. Papadopoulos, M. Miranda, A. E. Traynor, R. K. Burt

Research output: Contribution to journalArticlepeer-review

51 Scopus citations

Abstract

Evans syndrome is a rare disorder characterized by combined autoimmune thrombocytopenia (ITP) and autoimmune hemolytic anemia (AIHA). Standard treatments consist of transfusions, corticosteroids, splenectomy, IVIG, anabolic steroids, vincristine, alkylating agents, or cyclosporine. In a patient with refractory disease, an allogeneic hematopoietic stem cell transplant (HSCT) resulted in complete clinical and serologic remission for more than 30 months. Allogeneic HSCT may be the only current curative therapy for Evans syndrome but may also be complicated by significant toxicities.

Original languageEnglish (US)
Pages (from-to)903-905
Number of pages3
JournalBone Marrow Transplantation
Volume28
Issue number9
DOIs
StatePublished - 2001
Externally publishedYes

Keywords

  • Allogeneic stem cell transplantation
  • Evans syndrome

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Fingerprint

Dive into the research topics of 'Allogeneic stem cell transplantation for evans syndrome'. Together they form a unique fingerprint.

Cite this